Grey market tirzepatide: what TikTok's before-and-afters leave out

What did @louisadelgado3792 actually say?

Honestly? Not much, verbally. The transcript is song lyrics, not health claims. But the video does the talking anyway. The hashtags #tirzepatidejourney and #greymarket are doing real communicative work here, and 370,000 views means this content is reaching people who are likely drawing conclusions from it. The caption "Can't stop. Won't stop." paired with a before/after format implies sustained, successful use of tirzepatide sourced outside regulated channels. That framing is the claim, even if no words explicitly state it.

This is a pattern worth paying attention to. Creators increasingly let visuals and hashtags carry health messaging while song audio provides plausible deniability. The #greymarket tag is particularly notable here. It is not ambiguous. It signals the creator is sourcing tirzepatide outside of a licensed prescriber and pharmacy relationship, which raises questions that a catchy audio clip cannot answer.

Does the science back this up?

Tirzepatide itself has strong clinical backing. The before/after framing is not fantasy. But sourcing it through grey markets introduces risks that the data on the drug's efficacy cannot cancel out.

Tirzepatide (Zepbound, Eli Lilly) is a dual GIP and GLP-1 receptor agonist. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that participants on the highest dose lost an average of 20.9% of body weight over 72 weeks, which is genuinely impressive compared to anything that came before it. So the weight loss results people are posting are biologically plausible and backed by solid phase 3 data.

What the SURMOUNT trials did not study is compounded or grey-market tirzepatide of unknown concentration, sterility, or origin. The FDA has flagged compounded semaglutide and tirzepatide products for dosing errors and contamination risks. A 2023 FDA alert noted adverse events tied to compounded GLP-1 products, including hospitalizations. The drug works. The grey-market version of it is a different question entirely.

What did they get wrong (or right)?

The creator did not make specific false claims about tirzepatide's mechanism or dosing, so there is nothing to directly debunk in the transcript. That is worth noting. But the implicit framing gets some things wrong by omission.

Showing a before/after under #greymarket without any acknowledgment of sourcing risk, dosing uncertainty, or the absence of medical oversight is misleading by construction. Grey-market tirzepatide is not the same as prescribed Zepbound or Mounjaro. Compounded versions vary in concentration. Some products sold online as tirzepatide have been found to contain incorrect active ingredients or no active ingredient at all (FDA, 2024 drug shortage communications).

There is also no mention of side effects. Tirzepatide carries real gastrointestinal burden, particularly in early titration. The SURMOUNT-1 trial reported nausea in 31.1% of participants and vomiting in 19.9% at the highest dose. None of that context appears here. The "Can't stop. Won't stop." framing actively discourages the kind of cautious, supervised approach that makes this drug usable long-term.

What should you actually know?

Tirzepatide is a legitimate, well-studied drug. It is also prescription-only in every regulated market for good reason. Grey-market sourcing bypasses the medical oversight that makes it safer to use, not because the drug is exotic, but because dosing errors and contamination are real documented risks, not hypothetical ones.

If you are considering tirzepatide for weight management, the pathway matters. A licensed telehealth provider can assess contraindications (including personal or family history of medullary thyroid carcinoma, pancreatitis history, and drug interactions), supervise titration, and monitor for adverse effects. A grey-market supplier cannot do any of that.

The FDA placed compounded semaglutide on its list of drugs that should not be compounded when the shortage resolves, and similar scrutiny is being applied to tirzepatide. That regulatory trajectory exists because patient harm from unregulated versions has already occurred. A compelling before/after does not change that calculus.

• Do not source GLP-1 medications outside licensed pharmacy and prescriber channels.
• Before/after results reflect the studied drug under medical supervision, not grey-market equivalents.
• Side effect management requires titration oversight that self-sourcing cannot provide.